de Boer SA, Reijrink M, Abdulahad WH, et al. - A subanalysis from a randomized, placebo‐controlled trial (release study)was designed to evaluate whether T cells are decreased in people with type 2 diabetes mellitus and recruited by the dipeptidyl peptidase‐4 inhibitor linagliptin. Researchers evaluated tang cell levels in people with type 2 diabetes mellitus (T2DM) compared with matched healthy controls and after treatment with the dipeptidyl peptidase‐4 (DPP‐4) inhibitor Linagliptin. Individuals with T2DM were assigned randomly to 5 mg/day Linagliptin (n = 20) or placebo (n = 21) for 26 weeks. They distinguished tang cell frequency in peripheral blood mononuclear cells (CD3+CD31+CXCR4+) and levels of endothelial progenitor cells (EPCs) (CD34+CD133+KDR+) were also analyzed in whole blood. The results of this study indicate that DPP‐4 inhibitors may potentially exert beneficial effects on bone marrow‐driven vascular repair.